2024
A Multicenter Evaluation of the Impact of Therapies on Deep Learning-based Electrocardiographic Hypertrophic Cardiomyopathy Markers
Dhingra L, Sangha V, Aminorroaya A, Bryde R, Gaballa A, Ali A, Mehra N, Krumholz H, Sen S, Kramer C, Martinez M, Desai M, Oikonomou E, Khera R. A Multicenter Evaluation of the Impact of Therapies on Deep Learning-based Electrocardiographic Hypertrophic Cardiomyopathy Markers. The American Journal Of Cardiology 2024 PMID: 39581517, DOI: 10.1016/j.amjcard.2024.11.028.Peer-Reviewed Original ResearchCleveland Clinic FoundationHypertrophic cardiomyopathyMedian follow-up periodHypertrophic cardiomyopathy therapyMonitoring treatment responseFollow-up periodImpact of therapyAtlantic Health SystemLack of improvementOral alternativePost-SRTMedical therapyTreatment responseMulticenter evaluationInterventricular septumPercutaneous reductionMavacamtenTherapyPatientsClinic FoundationPoint-of-care monitoringECGECG imagesScoresHealth systemNatural Language Processing of Clinical Documentation to Assess Functional Status in Patients With Heart Failure
Adejumo P, Thangaraj P, Dhingra L, Aminorroaya A, Zhou X, Brandt C, Xu H, Krumholz H, Khera R. Natural Language Processing of Clinical Documentation to Assess Functional Status in Patients With Heart Failure. JAMA Network Open 2024, 7: e2443925. PMID: 39509128, PMCID: PMC11544492, DOI: 10.1001/jamanetworkopen.2024.43925.Peer-Reviewed Original ResearchConceptsFunctional status assessmentArea under the receiver operating characteristic curveClinical documentationElectronic health record dataHF symptomsOptimal care deliveryHealth record dataAssess functional statusStatus assessmentClinical trial participationProcessing of clinical documentsFunctional status groupCare deliveryOutpatient careMain OutcomesMedical notesTrial participantsNew York Heart AssociationFunctional statusQuality improvementRecord dataHeart failureClinical notesDiagnostic studiesStatus groupsArtificial Intelligence-Enhanced Risk Stratification of Cancer Therapeutics-Related Cardiac Dysfunction Using Electrocardiographic Images.
Oikonomou E, Sangha V, Dhingra L, Aminorroaya A, Coppi A, Krumholz H, Baldassarre L, Khera R. Artificial Intelligence-Enhanced Risk Stratification of Cancer Therapeutics-Related Cardiac Dysfunction Using Electrocardiographic Images. Circulation Cardiovascular Quality And Outcomes 2024 PMID: 39221857, DOI: 10.1161/circoutcomes.124.011504.Peer-Reviewed Original ResearchCancer therapeutics-related cardiac dysfunctionGlobal longitudinal strainLeft ventricular systolic dysfunctionCardiac dysfunctionBreast cancerNon-Hodgkin lymphoma therapyNon-Hodgkin's lymphomaVentricular systolic dysfunctionAssociated with worse global longitudinal strainRisk stratification strategiesHigh-risk groupMonths post-treatmentPost hoc analysisElectrocardiographic (ECGTrastuzumab exposureLymphoma therapySystolic dysfunctionAI-ECGBefore treatmentRisk biomarkersLongitudinal strainLow riskStratification strategiesHigher incidencePositive screenComparative Effectiveness of Second-Line Antihyperglycemic Agents for Cardiovascular Outcomes A Multinational, Federated Analysis of LEGEND-T2DM
Khera R, Aminorroaya A, Dhingra L, Thangaraj P, Pedroso Camargos A, Bu F, Ding X, Nishimura A, Anand T, Arshad F, Blacketer C, Chai Y, Chattopadhyay S, Cook M, Dorr D, Duarte-Salles T, DuVall S, Falconer T, French T, Hanchrow E, Kaur G, Lau W, Li J, Li K, Liu Y, Lu Y, Man K, Matheny M, Mathioudakis N, McLeggon J, McLemore M, Minty E, Morales D, Nagy P, Ostropolets A, Pistillo A, Phan T, Pratt N, Reyes C, Richter L, Ross J, Ruan E, Seager S, Simon K, Viernes B, Yang J, Yin C, You S, Zhou J, Ryan P, Schuemie M, Krumholz H, Hripcsak G, Suchard M. Comparative Effectiveness of Second-Line Antihyperglycemic Agents for Cardiovascular Outcomes A Multinational, Federated Analysis of LEGEND-T2DM. Journal Of The American College Of Cardiology 2024, 84: 904-917. PMID: 39197980, DOI: 10.1016/j.jacc.2024.05.069.Peer-Reviewed Original ResearchConceptsGLP-1 RAsSecond-line agentsGLP-1Antihyperglycemic agentsCardiovascular diseaseMACE riskGlucagon-like peptide-1 receptor agonistsSodium-glucose cotransporter 2 inhibitorsPeptide-1 receptor agonistsDipeptidyl peptidase-4 inhibitorsEffects of SGLT2isType 2 diabetes mellitusPeptidase-4 inhibitorsAdverse cardiovascular eventsCox proportional hazards modelsRandom-effects meta-analysisCardiovascular risk reductionTarget trial emulationProportional hazards modelCorrelation between hospital rates of survival to discharge and long-term survival for in-hospital cardiac arrest: Insights from Get With The Guidelines®-Resuscitation registry
Khera R, Aminorroaya A, Kennedy K, Chan P, Investigators A, Grossestreuer A, Moskowitz A, Ornato J, Churpek M, Starks M, Girotra S, Perman S. Correlation between hospital rates of survival to discharge and long-term survival for in-hospital cardiac arrest: Insights from Get With The Guidelines®-Resuscitation registry. Resuscitation 2024, 202: 110322. PMID: 39029583, PMCID: PMC11390317, DOI: 10.1016/j.resuscitation.2024.110322.Peer-Reviewed Original ResearchRisk-standardized survival ratesIn-hospital cardiac arrestWeighted kappa coefficientResuscitation RegistryLong-term survivalSurvivors of in-hospital cardiac arrestHierarchical logistic regression modelsCardiac arrestIn-hospitalLogistic regression modelsLong-term outcomesSurvival dataKappa coefficientHospital performanceIn-hospital survivalMedicare filesMedicare beneficiariesYears of ageHospitalization ratesPost-discharge survivalHospital dischargeRate of survivalMedicareHospitalRegression modelsPerformance of contemporary cardiovascular risk stratification scores in Brazil: an evaluation in the ELSA-Brasil study
Camargos A, Barreto S, Brant L, Ribeiro A, Dhingra L, Aminorroaya A, Bittencourt M, Figueiredo R, Khera R. Performance of contemporary cardiovascular risk stratification scores in Brazil: an evaluation in the ELSA-Brasil study. Open Heart 2024, 11: e002762. PMID: 38862252, PMCID: PMC11168182, DOI: 10.1136/openhrt-2024-002762.Peer-Reviewed Original ResearchConceptsPooled Cohort EquationsELSA-BrasilRisk scoreCardiovascular diseaseCVD eventsCommunity-based cohort studyArea under the receiver operating characteristic curveCVD risk scoreELSA-Brasil studyIncident CVD eventsMiddle-income countriesAdjudicated CVD eventsCardiovascular disease riskCVD scoreCohort EquationsNational guidelinesRisk stratification scoresWhite womenAge/sex groupsCohort studyProspective cohortLMICsSex/race groupsHigher incomeRisk discriminationDevelopment and multinational validation of an algorithmic strategy for high Lp(a) screening
Aminorroaya A, Dhingra L, Oikonomou E, Saadatagah S, Thangaraj P, Vasisht Shankar S, Spatz E, Khera R. Development and multinational validation of an algorithmic strategy for high Lp(a) screening. Nature Cardiovascular Research 2024, 3: 558-566. PMID: 39195936, DOI: 10.1038/s44161-024-00469-1.Peer-Reviewed Original ResearchElectronic health recordsAssociated with premature atherosclerotic cardiovascular diseaseElevated Lp(aHealth recordsUK BiobankPremature atherosclerotic cardiovascular diseaseMachine learning modelsAtherosclerotic cardiovascular diseaseCohort studyReal-world settingsTargeted screeningCardiovascular diseaseLearning modelsNovel targeted therapeuticsAlgorithmic strategiesCohortProbability thresholdScreeningClinical featuresValidation cohortElevated lipoproteinRisk inspectionARICLp(aReal-world evaluation of an algorithmic machine-learning-guided testing approach in stable chest pain: a multinational, multicohort study
Oikonomou E, Aminorroaya A, Dhingra L, Partridge C, Velazquez E, Desai N, Krumholz H, Miller E, Khera R. Real-world evaluation of an algorithmic machine-learning-guided testing approach in stable chest pain: a multinational, multicohort study. European Heart Journal - Digital Health 2024, 5: 303-313. PMID: 38774380, PMCID: PMC11104476, DOI: 10.1093/ehjdh/ztae023.Peer-Reviewed Original ResearchRisk of acute myocardial infarctionAssociated with lower oddsHospital health systemCoronary artery diseaseCardiac testingRisk of adverse outcomesUK BiobankHealth systemProvider-drivenLower oddsAssociated with better outcomesAcute myocardial infarctionBlack raceStable chest painFemale sexReal world evaluationDiabetes historyMulticohort studyFunction testsSuspected coronary artery diseaseYounger ageRisk profileAdverse outcomesMultinational cohortPost hoc analysisBurden of Ischemic Heart Disease and Its Attributable Risk Factors in North Africa and the Middle East, 1990 to 2019: Results From the GBD Study 2019
Aminorroaya A, Moghaddam S, Tavolinejad H, Aryan Z, Heidari B, Ebrahimi H, Naderian M, Shobeiri P, Ghanbari A, Rezaei N, Malekpour M, Haghshenas R, Rezaei N, Larijani B, Farzadfar F. Burden of Ischemic Heart Disease and Its Attributable Risk Factors in North Africa and the Middle East, 1990 to 2019: Results From the GBD Study 2019. Journal Of The American Heart Association 2024, 13: e030165. PMID: 37956220, PMCID: PMC10926818, DOI: 10.1161/jaha.123.030165.Peer-Reviewed Original ResearchConceptsDisability-adjusted life yearsBurden of ischemic heart diseaseDisability-adjusted life year ratesRates of ischemic heart diseaseIschemic heart diseaseRisk factorsMortality of ischemic heart diseaseEpidemiology of ischemic heart diseaseIschemic heart disease burdenHigh low-density lipoprotein cholesterolDietary risk factorsLost disability-adjusted life yearsYears of lifeHeart diseaseGBD studyPremature mortalityLow-density lipoprotein cholesterolSystolic blood pressureHighest burdenMetabolic riskBehavioral risksLife yearsPremature deathContemporary epidemiologyLipoprotein cholesterol
2023
Multinational patterns of second line antihyperglycaemic drug initiation across cardiovascular risk groups: federated pharmacoepidemiological evaluation in LEGEND-T2DM
Khera R, Dhingra L, Aminorroaya A, Li K, Zhou J, Arshad F, Blacketer C, Bowring M, Bu F, Cook M, Dorr D, Duarte-Salles T, DuVall S, Falconer T, French T, Hanchrow E, Horban S, Lau W, Li J, Liu Y, Lu Y, Man K, Matheny M, Mathioudakis N, McLemore M, Minty E, Morales D, Nagy P, Nishimura A, Ostropolets A, Pistillo A, Posada J, Pratt N, Reyes C, Ross J, Seager S, Shah N, Simon K, Wan E, Yang J, Yin C, You S, Schuemie M, Ryan P, Hripcsak G, Krumholz H, Suchard M. Multinational patterns of second line antihyperglycaemic drug initiation across cardiovascular risk groups: federated pharmacoepidemiological evaluation in LEGEND-T2DM. BMJ Medicine 2023, 2: e000651. PMID: 37829182, PMCID: PMC10565313, DOI: 10.1136/bmjmed-2023-000651.Peer-Reviewed Original ResearchType 2 diabetes mellitusSecond-line treatmentCardiovascular risk groupsDiabetes mellitusCardiovascular diseaseAntihyperglycaemic drugsLine treatmentRisk groupsObservational Health Data SciencesGlucagon-like peptide-1 receptor agonistsElectronic health recordsSodium-glucose cotransporter 2 inhibitorsCalendar year trendsPeptide-1 receptor agonistsUS databaseOutcomes of patientsCotransporter 2 inhibitorsAdministrative claims databaseSecond-line drugsHealth recordsSodium-glucose cotransporter-2 inhibitorsMedication useMetformin monotherapyGuideline recommendationsOutcome measuresRisk of incident cardiovascular diseases at national and subnational levels in Iran from 2000 to 2016 and projection through 2030: Insights from Iran STEPS surveys
Ebrahimi H, Masinaei M, Aminorroaya A, Aryan Z, Mehdipour P, Rostam-Abadi Y, Ahmadi N, Moghaddam S, Pishgar F, Ghanbari A, Rezaei N, Takian A, Farzadfar F. Risk of incident cardiovascular diseases at national and subnational levels in Iran from 2000 to 2016 and projection through 2030: Insights from Iran STEPS surveys. PLOS ONE 2023, 18: e0290006. PMID: 37611004, PMCID: PMC10446220, DOI: 10.1371/journal.pone.0290006.Peer-Reviewed Original ResearchConceptsCardiovascular disease riskRisk of cardiovascular diseaseNon-communicable disease risk factor surveillanceCardiovascular diseaseCVD riskWorld Health OrganizationRisk of incident cardiovascular diseaseRisk factor surveillanceFramingham 10-year CVD riskAdult Iranian populationIncident cardiovascular diseaseRisk factor modificationCardiovascular disease risk stratificationEvidence-based decisionsFramingham modelHealth policyNationally representative datasetFactor modificationRisk estimation modelIranian populationHealth OrganizationFraminghamSurvey's backgroundRiskSubnational levelUse of Smart Devices to Track Cardiovascular Health Goals in the United States
Aminorroaya A, Dhingra L, Nargesi A, Oikonomou E, Krumholz H, Khera R. Use of Smart Devices to Track Cardiovascular Health Goals in the United States. JACC Advances 2023, 2: 100544. PMID: 38094515, PMCID: PMC10718569, DOI: 10.1016/j.jacadv.2023.100544.Peer-Reviewed Original ResearchHealth goalsRisk of cardiovascular diseaseCardiovascular risk factorsNationally representative Health Information National Trends SurveyHealth Information National Trends SurveyU.S. adultsCardiovascular diseaseNational Trends SurveyRisk factors of hypertensionDigital health interventionsCardiovascular health goalsHealth-related goalsRisk of CVDFactors of hypertensionU.S. adult populationCardiovascular risk managementHigher educational attainmentLow-income individualsSmart devicesTrends SurveyImprove careHealth interventionsNational estimatesRisk factorsSurvey participantsDetection of left ventricular systolic dysfunction from single-lead electrocardiography adapted for portable and wearable devices
Khunte A, Sangha V, Oikonomou E, Dhingra L, Aminorroaya A, Mortazavi B, Coppi A, Brandt C, Krumholz H, Khera R. Detection of left ventricular systolic dysfunction from single-lead electrocardiography adapted for portable and wearable devices. Npj Digital Medicine 2023, 6: 124. PMID: 37433874, PMCID: PMC10336107, DOI: 10.1038/s41746-023-00869-w.Peer-Reviewed Original ResearchArtificial intelligenceRandom Gaussian noiseNoisy electrocardiogramGaussian noiseElectrocardiogram (ECGWearable devicesSingle-lead electrocardiogramPortable devicesSNRWearableNoiseDevice noiseRepositoryAI-based screeningIntelligenceDetectionDevicesNoise sourcesVentricular systolic dysfunctionModelElectrocardiogramSingle-lead electrocardiographyTrainingGlobal, Regional, and National Quality of Care Index (QCI) of Gastric Cancer: A Systematic Analysis for the Global Burden of Disease Study 1990-2017
Fattahi N, Ghanbari A, Djalalinia S, Rezaei N, Mohammadi E, Azadnajafabad S, Abbasi-Kangevari M, Aryannejad A, Aminorroaya A, Rezaei N, Azmin M, Ramezani R, Jafari F, Aghili M, Farzadfar F. Global, Regional, and National Quality of Care Index (QCI) of Gastric Cancer: A Systematic Analysis for the Global Burden of Disease Study 1990-2017. Journal Of Gastrointestinal Cancer 2023, 55: 247-262. PMID: 37365424, DOI: 10.1007/s12029-023-00950-3.Peer-Reviewed Original ResearchQuality of care indexQuality of careIncidence ratiosHigher quality of care indexQuality-of-care indicesGlobal Burden of Disease StudyBurden of Disease StudyLow SDI countriesSocio-demographic groupsPrevalence ratiosCare indexSDI countriesConclusionThe qualityGlobal burdenCancer deathDisease StudyCareHigher scoresNational qualityTherapeutic programScale 0ScoresEarly detectionNational levelCancer treatmentUse of Wearable Devices in Individuals With or at Risk for Cardiovascular Disease in the US, 2019 to 2020
Dhingra L, Aminorroaya A, Oikonomou E, Nargesi A, Wilson F, Krumholz H, Khera R. Use of Wearable Devices in Individuals With or at Risk for Cardiovascular Disease in the US, 2019 to 2020. JAMA Network Open 2023, 6: e2316634. PMID: 37285157, PMCID: PMC10248745, DOI: 10.1001/jamanetworkopen.2023.16634.Peer-Reviewed Original ResearchConceptsHealth Information National Trends SurveyUS adultsExacerbate disparitiesWearable device usersCardiovascular diseaseCardiovascular healthPopulation-based cross-sectional studySelf-reported cardiovascular diseaseCardiovascular disease risk factorsNational Trends SurveyOverall US adult populationCardiovascular risk factor profileSelf-reported accessAssociated with lower useUse of wearable devicesImprove cardiovascular healthLower household incomeLower educational attainmentUS adult populationRisk factor profileNationally representative sampleCross-sectional studyProportion of adultsTrends SurveyWearable device dataPersistence on Novel Cardioprotective Antihyperglycemic Therapies in the United States
Nargesi A, Clark C, Aminorroaya A, Chen L, Liu M, Reddy A, Amodeo S, Oikonomou E, Suchard M, McGuire D, Lin Z, Inzucchi S, Khera R. Persistence on Novel Cardioprotective Antihyperglycemic Therapies in the United States. The American Journal Of Cardiology 2023, 196: 89-98. PMID: 37012183, PMCID: PMC11007258, DOI: 10.1016/j.amjcard.2023.03.002.Peer-Reviewed Original ResearchConceptsSGLT-2iGLP-1RAsGlucagon-like peptide-1 receptor agonistsUnited States administrative claims databasesSodium-glucose cotransporter 2 inhibitorsCommercial insurancePeptide-1 receptor agonistsType 2 diabetes mellitusSodium-glucose cotransporter-2 inhibitorsConsistent medication useHealth outcome benefitsCotransporter 2 inhibitorsElevated cardiovascular riskInitiation of therapyAdministrative claims databaseProportion of daysCotransporter-2 inhibitorsRate of prescriptionAntihyperglycemic therapyCardiovascular riskDiabetes mellitusMedication useCardioprotective effectsPrescription practicesClaims databaseNovel DNMT3B Mutation in a Patient with Immunodeficiency, Centromeric Instability, and Facial Anomalies (ICF) Syndrome and a Bronchopulmonary Collateral Artery
Esmaeilzadeh H, Rezaei N, Aminorroaya A, Rayzan E, Shahkarami S, Seyedpour S, Zoghi S, Aryan Z, Somekh I, Rohlfs M, Klein C. Novel DNMT3B Mutation in a Patient with Immunodeficiency, Centromeric Instability, and Facial Anomalies (ICF) Syndrome and a Bronchopulmonary Collateral Artery. Endocrine Metabolic & Immune Disorders - Drug Targets 2023, 23: 410-415. PMID: 35996251, DOI: 10.2174/1871530322666220822141722.Peer-Reviewed Original ResearchConceptsRecurrent respiratory infectionsFacial anomaliesDNMT3B mutationsRecurrent infectionsCollateral arteriesFamily historyRespiratory infectionsHistory of recurrent respiratory infectionsAssociated with recurrent infectionsCentromeric instabilityFamily history of consanguinityRare autosomal recessive disorderRecurrent episodes of pneumoniaMonthly intravenous immunoglobulinProphylactic trimethoprim-sulfamethoxazolePrimary immune deficiencyBone marrow studyLow-set earsPatent ductus arteriosusEvaluation of neutropeniaEpisodes of pneumoniaHistory of consanguinityMild facial anomaliesAutosomal recessive disorderSystolic cardiac murmur
2022
Clinical Associations of Injuries Caused by Vasovagal Syncope: A Cohort Study From a Tertiary Syncope Unit
Tajdini M, Tavolinejad H, Aminorroaya A, Aryan Z, Jalali A, Alaeddini F, Sadeghian S, Yadangi S, Vasheghani‐Farahani A, Kalhor P, Bozorgi A. Clinical Associations of Injuries Caused by Vasovagal Syncope: A Cohort Study From a Tertiary Syncope Unit. Journal Of The American Heart Association 2022, 12: e027272. PMID: 36565190, PMCID: PMC9973565, DOI: 10.1161/jaha.122.027272.Peer-Reviewed Original ResearchConceptsAssociation of injuryIncidence of injuryAssociated with injuryVasovagal syncopeClinical associationsRate of injuryAssociated with lower riskRisk of injuryAt-risk individualsAbsence of prodromesRecurrent vasovagal syncopeYears of ageStanding positionCohort studySyncope clinicHigh-risk situationsRecurrent casesFemale sexProspective studyPatient characteristicsClinical evaluationSyncopeSyncope unitLow riskInjuryPharmacologic prevention of recurrent vasovagal syncope: A systematic review and network meta-analysis of randomized controlled trials
Behnoush A, Yazdani K, Khalaji A, Tavolinejad H, Aminorroaya A, Jalali A, Tajdini M. Pharmacologic prevention of recurrent vasovagal syncope: A systematic review and network meta-analysis of randomized controlled trials. Heart Rhythm 2022, 20: 448-460. PMID: 36509319, DOI: 10.1016/j.hrthm.2022.12.010.Peer-Reviewed Original ResearchConceptsHead-up tilt testPositive head-up tilt testNetwork meta-analysisRandomized controlled trialsVasovagal syncopeMeta-analysisPharmacological therapyPrimary outcomeRisk ratioRandom-effects network meta-analysisSystematic reviewPooled risk ratioConfidence intervalsHealth care systemLevel of evidenceCumulative ranking curve analysisPairwise meta-analysisTreatment optionsWeb of ScienceSyncopal eventsTilt testCare systemComparative efficacySecondary outcomesCochrane LibraryToll-like receptor 7 regulates cardiovascular diseases
Shafeghat M, Kazemian S, Aminorroaya A, Aryan Z, Rezaei N. Toll-like receptor 7 regulates cardiovascular diseases. International Immunopharmacology 2022, 113: 109390. PMID: 36330918, DOI: 10.1016/j.intimp.2022.109390.Peer-Reviewed Original ResearchConceptsTLR-7Toll-like receptorsIncreased risk of complete heart blockRisk of complete heart blockGranulocyte-macrophage colony-stimulating factorTLR-7 activationTLR-7 ligandsVascular smooth muscle cellsComplete heart blockImmune system's roleLeft ventricular remodelingColony-stimulating factorDamage-associated molecular patternsSmooth muscle cellsInnate immune receptorsPro-inflammatory natureRisk of thrombus formationHeart blockImmune cellsVentricular remodelingIncreased riskMuscle cellsAtherosclerotic plaque formationSingle-stranded ribonucleic acidViral infection